Tuhura Biosciences, Inc/nv 8-K filings

TuHURA Biosciences announced its second quarter 2026 financial results, highlighting progress in its immuno-oncology pipeline and a $50 million credit facility extending cash runway.

TuHura Biosciences, Inc. has drawn an additional $1.5 million under its existing revolving credit facility for general corporate purposes.

TuHura Biosciences, Inc. has drawn an additional $1.9 million under its revolving credit facility for general corporate purposes.

TuHURA Biosciences has initiated its first drawdown of $1.7 million from a previously established $50 million revolving credit facility.

TuHURA Biosciences reports Q1 2026 financial results and secures a $50 million credit facility to extend its cash runway into 2028.

TuHURA Biosciences filed an amendment to its 8-K to correct errors in previously reported pro forma financial statements following its acquisition of Kineta.

TuHURA Biosciences has entered into a $50 million revolving credit facility with Parkview Holdings One LLC to fund operations and development programs.

TuHURA Biosciences reports pro forma financial results for 2025 post-Kineta acquisition and announces executive bonus and salary adjustments.

TuHURA Biosciences announced its full year 2025 financial results and provided a corporate update, highlighting progress in its immuno-oncology clinical programs and strategic acquisitions.

TuHURA Biosciences, Inc. received a Nasdaq notice for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day grace period to regain compliance.

TuHURA Biosciences, a Phase 3 immuno-oncology company, announced a registered direct offering totaling $15.6 million through the sale of common stock and warrants across three tranches.

TuHURA Biosciences extended its loan availability period and secured an additional $1.5 million, bringing total funding to $3.0 million, accompanied by the issuance of new warrants.

TuHURA Biosciences' Form S-3 shelf registration statement, covering the resale of over 9 million shares, has become effective, superseding a prior S-1 filing.

TuHURA Biosciences, Inc. filed an 8-K detailing unaudited pro forma financial statements for 2024 and 2025, reflecting its recent acquisitions of Legacy TuHURA and Kineta.

TuHURA Biosciences reports Q3 2025 financial results, highlights Phase 3 trial progress, and announces a $50 million ATM facility.

TuHURA Biosciences entered an At The Market Offering Agreement to sell up to $50 million in common stock for working capital and general corporate purposes.

TuHURA Biosciences provides comprehensive updates on its business, operations, and risk factors following its recent mergers with Kintara Therapeutics and Kineta, Inc., detailing clinical trial progress and financial position.

TuHURA Biosciences secures a $3M bridge loan from Matthew Nachtrab Revocable Trust, pledging ImmuneFx™ patents.

TuHURA Biosciences, Inc. accelerated the purchase of $3.2 million from its private placement, extending the expiration of 1.5 million warrants for participating investors.

TuHURA Biosciences reported its second quarter 2025 financial results, highlighting the acquisition of Kineta, initiation of a Phase 3 trial for IFx-2.0, and successful equity financing.

TuHURA Biosciences, Inc. finalized its acquisition of Kineta, Inc., integrating Kineta's lead oncology asset TBS-2025 and securing significant new financing to advance its clinical pipeline.

TuHURA Biosciences, Inc. has successfully completed its acquisition of Kineta, Inc., integrating a Phase 2 ready VISTA inhibiting monoclonal antibody, TBS-2025, into its immuno-oncology pipeline and unlocking a new tranche of PIPE financing.

TuHURA Biosciences, Inc. has increased its authorized common stock from 75 million to 200 million shares following stockholder approval and the filing of an amendment with the Nevada Secretary of State.

TuHURA Biosciences, Inc. and Kineta, Inc. stockholders have overwhelmingly approved all proposals related to their proposed merger, including an increase in authorized shares and reincorporation to Delaware, signaling the imminent closing of the transaction.

TuHURA Biosciences, Inc. announced increased base salaries for its CEO and CFO effective June 6, 2025, and disclosed substantial 2024 executive compensation, including significant stock awards and severance payments.

TuHURA Biosciences, Inc. has entered into a securities purchase agreement for a private placement of approximately $12.6 million, alongside an additional $3.0 million from warrant exercises, to fund its Phase 3 trial, Kineta merger, and pipeline advancement.

TuHURA Biosciences announces its Q1 2025 financial results, highlights clinical trial advancements, and anticipates the closing of the Kineta, Inc. acquisition.

TuHURA Biosciences announces the appointment of Dr. Craig Tendler to the Nominating and Corporate Governance Committee, effective May 5, 2025.

TuHURA Biosciences and Kineta have amended their merger agreement, extending the end date to June 30, 2025, and revising the terms of the merger consideration, including adjustments to the stock and cash components.

TuHURA Biosciences reports its 2024 financial results, provides a corporate update focusing on its Phase 3 trial for IFx-2.0 and the planned acquisition of Kineta, Inc.